Novavax is aiming to seek Emergency Use Authorization for its COVID-19 vaccine NVX-CoV2373 later this spring. If the U.S. Food and Drug Administration gives it the green light, the Maryland-based company could see revenue of approximately $1.8 billion in sales by the end of the year.
A panel of experts discusses the future landscape for vaccine development and future opportunities for biotech companies.
Emergent BioSolutions’ contract development and manufacturing (CDMO) business is playing a crucial role in supporting the battle against COVID-19. The company has contracted with multiple vaccine makers, including AstraZeneca and Johnson & Johnson, to manufacture the preventative medications.
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization Rolling reviews have commenced by FDA, MHRA, EMA and Health Canada GAITHERSBURG, Md., February 4, 2021 [….]
ATCC, the world’s premier biological materials management and standards organization, today announced that it has been awarded a three-year, $9.86 million task order contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to manage and operate its HIV Reagent Program, formerly known as the AIDS Reagent Program. ATCC is tasked to supply the HIV/AIDS research community with no-cost, high-quality materials supporting the development and evaluation of therapeutics, vaccines, and diagnostics.
2020 brought about a lot of growth across the BioHealth Capital Region (BHCR) as dozens of organizations responded with urgency to address the COVID-19 pandemic.
Vaccine Development Companies’ Approach to Cultivating Patient Confidence, Trust in COVID-19 Vaccine
In early November, the Novavax COVID-19 vaccine received fast track designation by the Food and Drug Administration (FDA) and has begun its Phase 3 trials in the United States and Mexico.
With the unprecedented speed of vaccine development amid the COVID-19 pandemic, questions have emerged regarding the future of vaccinology beyond the coronavirus. In a panel on vaccinology in the 21st century hosted by Noble Life Sciences, scientists discussed the vaccine platforms available to us now, the significance of mRNA vaccines and the emergence of new combination vaccines.
Noble Life Sciences Hosts Panel Discussion “Vaccinology in the 21st Century: Engineering an Effective Vaccine Platform”
Rockville, Maryland’s Advanced BioScience Laboratories, Inc. (ABL) is a rapidly growing biotech company that provides expert contract manufacturing and laboratory research services to customers across the globe. The company delivers best-in-class GMP manufacturing and immunology solutions for gene therapies, oncolytics, vaccines, and other immunotherapeutics to life science organizations, and government agencies.